Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pape, L.
Right arrow Articles by Offner, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pape, L.
Right arrow Articles by Offner, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 276-280
© 2002 European Renal Association-European Dialysis and Transplant Association

Single centre experience with basiliximab in paediatric renal transplantation

Lars Pape1,, Juergen Strehlau1, Thomas Henne1, Kay Latta1, Bjoern Nashan2, Jochen H. H. Ehrich1, Juergen Klempnauer2 and Gisela Offner1

Departments of 1 Paediatric Nephrology and 2 Transplant Surgery, Hannover Medical School, Hannover, Germany

Background. Introduction of IL-2-receptor antagonists has led to significantly decreasing numbers of acute rejection episodes in renal transplantation in adults. No data are available in paediatric recipients.

Methods. Between 1997 and 2000, 78 renal transplantations were performed in 77 children aged 0.5–16 years. Basiliximab, cyclosporin A (CsA) and prednisolone were administered in 48 children (age 7.8±5.3 years) and compared with 29 children (age 7.3±5.2 years) receiving CsA and prednisolone only. The number of acute rejections, survival, glomerular filtration rate (GFR) and side effects were determined for 3 years after transplantation.

Results. All 77 patients survived the observation period. One year graft survival in the basiliximab group was 95%, which is similar to the comparison group (93%). Children receiving basiliximab showed a lower incidence of acute rejection than the comparison group (14% vs 34%). The calculated GFR was lower in the basiliximab group when discharging from hospital, with 51 compared with 66 ml/min/1.73 m2 in the non-basiliximab group. This was associated with higher CsA trough levels (214 vs 174 ng/ml) in the basiliximab patients. After 1 year the GFR was comparable in both groups (58 vs 52 ml/min/1.73 m2).

Conclusions. Basiliximab offers excellent allograft survival, a lower incidence of acute rejections and almost no side effects. Therefore it can be recommended for routine immunosuppressive therapy in paediatric renal transplantation.

Keywords: acute rejection; basiliximab; paediatric; renal transplantation; survival

Correspondence and offprint requests to: Lars Pape, Department of Pediatric Nephrology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30623 Hannover, Germany. Email: larspape{at}t\|[hyphen]\|online.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
N J A Webb, R Johnson, and R J Postlethwaite
Renal transplantation
Arch. Dis. Child., October 1, 2003; 88(10): 844 - 847.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.